poster

Clinical Dilemmas in Schizophrenia Treatment and the Potential Place in Therapy of Long-acting Antipsychotic Agents

Abstract: Introduction: Treatment nonadherence in schizophrenia is a continuing challenge, but can be improved with use of long-acting injectable antipsychotic agents (LAIs). Although wel...

01/19/2023

Influence of Cultural Differences and Genetic Polymorphisms on Schizophrenia Management: An Exploratory Targeted Literature Review

Abstract: Objective: Cultural differences impact schizophrenia management across countries and may complicate the evaluation of new therapeutics. Genetic polymorphisms are associated with...

01/19/2023

Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement—An Interactive Digital Platform to Educate on Schizophrenia Care

Abstract: Introduction: Healthcare professionals (HCPs) face unique challenges when managing patients with schizophrenia. Educational initiatives targeting the most common dilemmas encoun...

01/19/2023

Clinician Interaction With a Prescription Digital Therapeutic for OUD: Engagement and Outcomes

Abstract: Background: Prescription digital therapeutics (PDTs) are U.S. Food and Drug Administration-authorized software-based treatments delivered on mobile devices. The reSET-O PDT for ...

01/19/2023

Abstract: Aim: Prescription digital therapeutics (PDTs) are software-based treatments evaluated for safety and effectiveness by the FDA. This study evaluated associations between age and ...

01/19/2023

Hypertension Onset Among Patients With Narcolepsy Newly Treated With Sodium Oxybate

Abstract: Introduction: Sodium oxybate, a recommended narcolepsy treatment, is a high sodium–containing drug with consequent label warnings. The sodium-hypertension relationship is well e...

01/19/2023

A New Methodological Approach to Improve the "Real Word" Effectiveness of Ketamine Infusion Therapy for Treatment-Resistant Depression

Abstract: Objective: Ketamine is recognized as a rapidly acting antidepressant; however, discrepancies exist between the "Efficacy" reported in research studies (70-85%) versus significan...

01/19/2023

Dispelling Myths and Misconceptions Surrounding the Use of Long-acting Injectable Antipsychotic Agents for Treatment of Schizophrenia

Abstract: Introduction: Schizophrenia affects over 3 million people in the United States. Despite data supporting the use of long-acting injectable antipsychotic agents (LAIs), myths and ...

01/19/2023

Dose Proportionality and the Effect of Sprinkling on the Bioavailability of Once-Daily Extended-Release Lorazepam

Abstract: Lorazepam, traditionally administered as immediate-release tablets, is an allosteric GABA-receptor modulator approved for the treatment of anxiety disorders. A once-daily, exten...

01/19/2023

A Network Analysis of Borderline Personality Disorder Symptoms: a real-world data (RWD), electronic health record (EHR) study

Abstract: Background Borderline Personality Disorder (BPD) is a heterogeneous disorder. The current study used network analysis of Electronic Health Record (EHR) data to explore associati...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products